Pereira Bernardo Acacio Santini, Souza-Silva Franklin, Silva-Almeida Mariana, Santos-de-Souza Raquel, Gonçalves de Oliveira Luiz Filipe, Ribeiro-Guimarães Michelle Lopes, Alves Carlos Roberto
Laboratorio de Biologia Molecular e Doenças Endemicas, Instituto Oswaldo Cruz - Fiocruz, Avenida Brasil, 4365 Pavilhao Leonidas Deane, sala 209A, Manguinhos, Rio de Janeiro, RJ - CEP: 21040-900, Brasil.
Curr Drug Targets. 2014;15(12):1121-31. doi: 10.2174/1389450115666141016150007.
This review presents and discusses the current status and perspectives of leishmaniasis treatment, with a special focus on the use of proteinase inhibitors. The history of treatment development, the first- and second-choice modern drugs and the advantages and disadvantages of using proteinases inhibitors as leishmanicidal treatments are presented and discussed. The reports gathered herein confirm the potential usefulness of proteinases inhibitors as an alternative or complement to the current leishmaniasis treatments. They also support the hypothesis that a combined treatment with multiple proteinase inhibitors may be efficient against Leishmania infections in vertebrate hosts.
本综述介绍并讨论了利什曼病治疗的现状与前景,特别关注蛋白酶抑制剂的应用。文中介绍并讨论了治疗方法的发展历程、现代一线和二线药物,以及使用蛋白酶抑制剂作为杀利什曼原虫治疗方法的优缺点。本文收集的报告证实了蛋白酶抑制剂作为当前利什曼病治疗方法的替代或补充的潜在用途。这些报告还支持以下假设,即多种蛋白酶抑制剂联合治疗可能对脊椎动物宿主中的利什曼原虫感染有效。